On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 519.47% and ...

Conditions are getting a bit more challenging for the drugmaker.

Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 23 trades. If we consider the specifics of ...